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Background: Acute and chronic brain damages including neurodegenerative diseases are a group of
neuroinflammation-associated diseases characterized by cognitive function defect and progressive neuron loss. The
pathophysiological procession of brain damages involves the overexpression of cyclooxygenase (COX)-2. Owing to
the limited benefit to chronic brain damage and the late adverse effect of COX-2 inhibitors, the COX downstream
signaling pathway has become a focus in neurological research. In order to explore the mechanism of aluminum
neurotoxicity and the importance of COX2 downstream signaling pathways to chronic brain damage, the present
study was designed to simultaneously observe the prostaglandin (PG) contents, and the expressions of PG synthases
and PG receptors of hippocampus in a rat model induced by chronic administration of aluminium gluconate.
Methods: A rat model of chronic brain damage was established by chronic intragastric administration of aluminium
gluconate (Al3+ 200 mg/kg per day, 5d a week for 20 weeks). PG contents, the expressions of PG synthases, and the
expressions of PG receptors in rats were measured by ELISA, RT-PCR and Western blotting, respectively.
Results: Chronic aluminium gluconate administration resulted in hippocampal neuron injury and learning and memory
disorders in rats. Aluminium gluconate administration also resulted in increased levels of PGE2, PGD2, TXA2, PGI2, and PGF2α
in rat hippocampus. The DP1, EP2, IP, mPGES-1, EP4, PGIS and TXAS mRNA expressions, and the DP1, EP2 and IP protein
expressions significantly increased in the Al-treated hippocampus, while the EP3 and FP mRNA and protein expressions
and the TP mRNA expression decreased.
Conclusions: The PGS/PGs/PG receptors signaling pathway in chronic aluminium gluconate-overloaded rat hippocampus
is disturbed, which may be involved in the mechanism of aluminium neurotoxicity.
Keywords: Aluminium gluconate, Neurotoxicity, Cyclooxygenase, Prostaglandins, Prostaglandin synthases, Prostaglandin
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Aluminum (Al), which accounts for about 8% of the
earth's crust composition, is the most ubiquitous metal
in water, soil and air and is extensively used in modern
daily life. Therefore, we unavoidably take in Al through
various routes, including the use of pharmaceuticals (e.g.
antacids, buffered analgesics, antiulceratives, and anti-
diarrheal drugs). The daily Al intake by humans through
the gastrointestinal tract is up to 126–5000 mg/day [1],* Correspondence: 1139627371@qq.com
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unless otherwise stated.corresponding to 12–500 mg/kg daily by rats converted
via the body surface area index between humans and
rats [2]. However, the physiological action of Al on
humans is unclear. Since the first report of Al toxicity to
humans at early 1970s, it has been identified that Al
overload could cause severe brain damage and neurode-
generation [3]. In particular, Al neurotoxicity could be
involved in the pathogenesis of Alzheimer’s disease (AD)
and Al was detected in senile plaques and neurofibrillary
tangles in the brain tissues from AD patients [1,3]. The
mechanism of Al neurotoxicity is still unknown. As re-
ported, the Al-induced neuronal injury is closely relatedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[4-6].
Cyclooxygenase (COX) can catalyze arachidonic acid
(AA) to bioactive prostaglandin (PG)H2. PGH2 can be
further catalyzed by specific PG synthases (PGS) to PGs,
including PGE2, PGD2, thromboxane A2 (TXA2), prosta-
cyclin (PGI2), and PGF2α. COX has two isoenzymes: the
constitutive COX-1 and the inducible COX-2. COX-1 is
constitutively expressed in many tissues, including the
brain and especially the microglia. COX-2 is also highly
and basally expressed in many tissues, including brain
neuronal cells. COX-2 is mainly present in the cell bodies
and dendritic regions of neurons of hippocampus, cerebral
cortex, and amygdale [7]. COX-2 expression in neurons
can be induced by excitotoxic insults,transient global cere-
bral ischemia and oxidative stress as well as inflammatory
mediators [8,9]. Hippocampal and frontal cortex neuronal
COX-2 mRNA and protein levels will significantly in-
crease in the brains of AD patients [5,10].
We previously found that chronic intragastric (i.g.)
administration of aluminium gluconate (Al3+ 200 mg/kg
per day) caused significant increase of hippocampal
metal ion levels (Al, Fe, Mn, Cu and Zn), and induced
learning and memory function disorders in rats [11].
We also find that the aluminium gluconate administration-
induced chronic brain damage in rats can be remarkably
prevented by meloxicam, a COX-2 inhibitor [12]. These
findings suggest that the over-expression of COX-2 may
play an important role in the occurrence of neuron damage
and neurodegeneration, and the inhibitors of COX-2 may
prevent the acute and chronic brain damages induced by
aluminium gluconate.
However, the potential beneficial effect is limited to
some non-steroidal antiinflammatory drugs (NSAIDs)
since two randomized trials show that the use of cele-
coxib or naproxen could not prevent AD, or improve
the cognitive function of AD patients [13,14]. A clinical
trial shows that NSAIDs act differently at various stages
of the disease and even have an adverse effect at later
stages of AD [15]. So, the immediate goal in experimen-
tal research is to focus on the specific COX-dependent
signaling sub-pathways and thus to observe the potential
therapeutic effect for modifying AD development and
avoiding the toxicity of NSAIDs.
PGE2, a product of PGH2 catalyzed by PGE synthase
(PGES), can activate the G-protein-coupled PGE recep-
tors (EP), including EP1, EP2, EP3 and EP4. Blockage of
EP1 signaling can partially protect neurons from cere-
bral ischemic injury and suppress Aβ accumulation
[16,17]. However, activation of EP1 leads to neurodegen-
eration, which can be prevented by the use of selective
EP1 antagonists [18]. PGE2 is able to both stimulate
amyloid-β formation and reduce the occurrence of
amyloid-β-induced neurodegeneration [19,20]. Activationof EP3 contributes to ischemic excitotoxicity in ischemic
stroke models [21]. Administration of an EP4 antagonist
can suppress the development of experimental allergic en-
cephalitis (EAE) in vivo [22]. Oral administration of AE3-
208, a specific EP4 antagonist, will improve the cognitive
performance of APP23 mice, transgenic mice expressing
mutant APP [23]. However,it was reported that the activa-
tion of EP4 has antiinflammatory effects [24].
The formation of PGD2 is induced by PGD synthase
(PGDS) on PGH2. PGD2 receptor (DP) has two sub-
types viz. DP1 and DP2. The activation of DP1 is pri-
marily associated with anti-inflammation, but DP1 also
has proinflammatory effects [25]. Since DP2 is involved
in the development of inflammatory diseases, its block-
age may be a novel therapeutic way for control of brain
damages and neurodegeneration [26].
Prostacyclin (PGI2) is derived from PGH2 via the ac-
tion of PGI2 synthase (PGIS) and acts mainly on the
membrane-bound PGI2 receptor (IP). As reported, IP
knockout (IP−/−) mice suffered from more severe myo-
cardial ischemic injury compared with their wild-type
counterparts [27]. PGI2 analogs can prevent ischemia re-
perfusion brain damage in gerbils and hypertensive rats
[28]. PGH2 can be converted by Thromboxane A2 syn-
thase (TXS) to TXA2, and then TXA2 activates TXA2
receptor (TP), which plays a pathophysiological role in
the development of cardiovascular diseases and stroke.
Presynaptic activation of TP will improve the glutamate
release, while postsynaptic activation will inhibit synaptic
transmission [29]. A selective TP antagonist could pre-
vent atherothrombosis and ischemic stroke [30].
PGF2α is a major prostanoid biosynthesized from
PGH2 by PGF synthase (PGFS), and may undertake
some important pathophysiological functions via PGF2α
receptor (FP) in an autocrine or paracrine manner. The
use of FP−/− mice and FP inhibitor indicates that FP
could enhance brain damage by cerebral ischemia and
excitotoxicity insult [31,32].
These studies indicate the presence of a much com-
plex PG network in the COX downstream signaling
pathways and that it is unclear which strategy should be
employed for treatment of brain damage and neurode-
generation: to activate or block the same PG receptor.
The debate in these experimental findings can be attrib-
uted to the differences in tissue sources, methodologies,
and especially animal models. Therefore, it is necessary
to simultaneously observe the changes of PG synthases/
PGs content/PG receptors pathways with the same ani-
mal model.
The present study was designed to simultaneously ob-
serve the contents of PGs (PGE2, PGD2, TXA2, PGI2,
and PGF2α), and the expressions of PG synthases
(PGES, PGDS, TXAS, PGIS, and PGFS) and PG recep-
tors (EP1-4, DP1-2, FP, IP and TP) in rat hippocampus
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The results in this study will help to explore the mech-
anism of aluminium neurotoxicity and the importance
of COX-2 downstream signaling pathways to the occur-
rence of chronic brain damage.
Methods
Reagents
The following reagents were obtained commercially: a
BioFlux reverse transcription (RT) kit and a BIOZOL™
total RNA extraction kit (Hangzhou Bioer Technology
Co., Ltd.); a Premix PCR kit (Beijing ComWin Biotech
Co., Ltd.); mouse antirat β-actin monoclonal antibodies
and goat antimouse horseradish peroxidase (HRP)-con-
jugated secondary antibodies (Zhongshan Goldbridge
Technology Co., Ltd., Beijing); rabbit antirat FP (DP1,
EP1-4, IP and TP) monoclonal antibodies and goat anti-
rabbit HRP-conjugated secondary antibodies (Cayman,
USA); a BeyoECL chemiluminescence detection kit and
a bicinchoninic acid (BCA) protein detection kit
(Beyotime Institute Biotechnology, Shanghai).
Animals and experimental protocol
A total of 34 male Sprague Dawley rats, aged 8 weeks
old and weighing 200–250 g at the beginning of experi-
ments, were purchased from the Laboratory Animal
Center of Chongqing Medical University (No. SCXK
(Yu) 2010–0001). They were housed in standard condi-
tions: 22 ± 2°C, 50 ± 2% humidity, and 12 h light/dark cycles
(light from 8:00–20:00). All experimental procedures on an-
imals were approved by the Chongqing Medical University’s
Institutional Animal Ethics Committee. The 34 rats were
randomly divided into two groups: a control group and an
Al-treated group (each n = 17). The Al-treated group re-
ceived chronic i.g. administration of aluminium gluconate
(Al3+ 200 mg/kg per day), 5 days per week for 20 continu-
ous weeks. The control group was treated with an equal
volume of sodium gluconate [11,33,34].
Morris Water Maze test
On the following day after aluminium gluconate admin-
istration was completed, the rats in each group were
subjected to a spatial learning and memory test using a
DMS-2 Morris water maze (Institute of Materia Medica,
Chinese Academy of Medical Sciences, Beijing) with a
height of 0.5 m, diameter of 1.5 m, water depth of 0.4 m
and temperature of 23 ± 2°C. The rats were allowed to
learn how to navigate the maze for four days. On the
fifth day, spatial memory was tested as previously re-
ported [35]. The rats in each group received a probe trial
in which the platform was removed. The time for a rat
to pass through the place, where the platform was previ-
ously placed, was called the time to explore the platform
(exploring time).Pathomorphological observation
Six days after aluminium gluconate administration was
completed, 4 rats from each group were selected for
histopathological observation. According to a reported
method [33], the rats were intraperitoneally anesthe-
tized with 1 mL/100 g of 4% chloral hydrate and trans-
cardially perfused with 150 mL of 0.9% saline
containing 375U heparin, as well as 200 mL of 4.0%
paraformaldehyde fixing solution containing 0.1 M
phosphate buffer solution (PBS, pH 7.2). The cerebral
tissue was isolated and made into 5-μm-thick coronal
sections, which were stained by hematoxylin and eosin
(H&E). The pathological changes in hippocampal nerve
cells were observed by light microscopy. Injured neu-
rons and dead nerve cells were identified by their acido-
philic (eosinophilic) cytoplasm, pyknotic nuclei and
nucleoli disappearance under light microscopy [36].
Ten consecutive fields were selected from the dorsal
hippocampal CA1 subfield of each section. Then the
whole numbers of intact nerve cells were counted using
a microscope at 400× and the extent of cell death was
estimated.Measurement of malondialdehyde (MDA) content and
superoxide dismutase (SOD) activity
Six days after aluminium gluconate administration was
completed, the brains of four rats from each group were
removed and frozen at −80°C. Hippocampal tissues were
homogenized with saline at a weight- volume ratio of 1:9,
followed by centrifugation. The supernatants were col-
lected to detect MDA content and SOD activity according
to the manufacturer’s manual (Jiancheng Bioengineering
Ltd, Nanjing). The protein content of each sample was
measured by biuret spectrophotometry.Detection of PGE2, PGD2, TXA2, PGI2, and PGF2α levels
Six days after aluminium gluconate administration was
completed, the brains of the four rats from each group
were removed. Hippocampal tissue homogenates from
each group (n = 4) were prepared with saline at a
weight-volume ratio of 1:9 and then centrifuged at
14000 g × 10 min under 4°C. After that, the supernatants
were collected for measurement of PGE2, PGD2,
TXA2, PGI2, and PGF2α levels according to the man-
ual of the enzyme-linked immunosorbent assay
(ELISA) kit (Cayman, USA). Since PGI2 and TXA2 can
be easily metabolized, their levels were represented by
their metabolites 6-keto-PGF1α and TXB2, respectively.
In order to avoid the post-mortem production of pros-
tanoids from oxylipids, we added indomethacin, a non-
selective inhibitor of COX-1 and COX-2, according to
the manual of the ELISA kit.
Table 1 The primer sequences for RT-PCR amplification
and lengths of the products
mRNA primer Sequence Product length
H-PGD F: 5’-TCTTGGGTCTCTTGGGATTTC-3’ 474 bp
R: 5’- GGTCCTTGCTAAAGGTGATGA-3’
cPGES F: 5’-GGTACGACCGAAGGGACTATG-3’ 421 bp
R: 5’-GAATCATCATCTGCTCCGTCT-3’
mPGES-1 F: 5’-GTGATGGAGAACAGCCAGGT-3’ 307 bp
R: 5’-TGAGGACCACGAGGAAATGTA-3’
PGIS F: 5’-TTTTACAGATGACCGCACTCC-3’ 416 bp
R: 5’-GAAATGAGTCAGCAGCAGGAC-3’
TXAS F: 5’-TGACTCTGTCCGTGGTTCTCT-3’ 492 bp
R: 5’-AACACCTCTGGATGTCGAATG-3’
DP1 F: 5’-TTCTACCAAAGGCACATCACC-3’ 390 bp
R: 5’-AGCCAGCAGAACAAAGTGGT-3’
EP1 F: 5’-CAGGTGAAGTGGATCTGAAAGG-3’ 359 bp
R: 5’-GACGAACAACAGGAAGGTGGC-3’
EP2 F: 5’-GCGAGAGTCGTCAGTATCTCCT-3’ 400 bp
R: 5’-CGCCTGTAGAAGTAAGGGTGTC-3’
EP3 F: 5’-GTATGCCAGCCACATGAAGAC-3’ 376 bp
R: 5’-ACACATGATCCCCATAAGCTG-3’
EP4 F: 5’-GTGCTCATCTGCTCCATTCCG-3’ 380 bp
R: 5’-CGAGGCTGCTTTCAGTTAGGT-3’
FP F: 5’-AATAATTCCCCAGTGACCTGTG-3’ 254 bp
R: 5’-GATGCTTGCTGATTCTCCTTCT-3’
IP F: 5’-CCTCTCATTGTAGGTGGCAGA-3’ 416 bp
R: 5’-GCGTACAGGTAGGGATGACTG-3’
TP F: 5’-AGATGATGGTTCAGCTCGTAGG-3’ 403 bp
R: 5’-GTAACTCCATCCCACCAAACAT-3’
β-actin F: 5′-cacccgcgagtacaaccttc-3′ 207 bp
R: 5′- cccatacccaccatcacacc-3
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of mRNA of PG synthases and PG receptors
After the learning and memory function test was com-
pleted, brain hippocampi of four rats from each group
were removed and frozen at −80°C. Then the mRNA ex-
pressions of PG synthases and PG receptors in the
hippocampi were detected by RT-PCR. The tested PG
synthases include cytosolic PGES (cPGES), microsomal
PGES (mPGES)-1, hematopoietic PGDS (H-PGDS),
prostacyclin synthase (PGIS) and thromboxane synthase
(TXAS). The mRNA expression of lipocalin-type PGDS
(L-PGDS) was not measured in this study since its
cDNA sequences could be found in NCBI Genbank. The
tested PG receptors include EP1-4, DP1, FP, IP and TP.
Total RNA was extracted from rat brain hippocampi
using BIOZOL reagents according to the directions of
the total RNA extraction kit. The primer sequences used
for RT-PCR amplification and the lengths of the prod-
ucts are listed in Table 1.
Two-step RT-PCR was carried out according to direc-
tions of the BioFlux RT kit and the Premix PCR kit. The
total reaction volume for RT was 10 μL, containing 2 μL
of 5× RT buffer, 1 μL of 10 mM dNTP mixture, 0.5 μL
of 10 pmol/μL oligo (dT), 0.5 μL of 10 U/μL RNase in-
hibitor, 0.5 μL of AMV reverse transcriptase (5 U/μl),
1 μL (1 μg) of RNA template, and 4.5 μL of RNase-free
H2O. The RT conditions were 50°C for 45 min, 95°C for
5 min and ice-bath for 5 min. The total volume for PCR
was 25 μL, containing 12.5 μL of 2 × Taq MasterMix,
1.0 μL of cDNA, 1.0 μL of 10 μM forward primer, 1.0 μL
of 10 μM reverse primer, and 9.5 μL of sterile double-
distilled water. The PCR conditions were 94.0°C for
2 min, 35 cycles of 94.0°C for 30 s, 57.8°C for H-PGDS
(57.4 for cPGES, 59.4 for mPGES-1, 59.7 for PGIS
mRNA, 57.4 for TXAS, 57.0 for DP1, 59.0 for EP1, 57.0
for EP2, 57.0 for EP3, 59.4 for EP4, 57.0 for FP, 57.4 for
IP, 57.0 for TP and 57.0 for β-actin) for 30 s and 72.0°C
for 30 s, followed by extension at 72.0°C for 5 min.
The PCR products were visualized after 2% agarose gel
electrophoresis. The integrated gray values of the prod-
uct bands were measured using a BioRad gel imaging
and analysis system (Hercules, CA, USA). The mRNA
levels of cPGES, mPGES-1, H-PGDS, PGIS, TXAS, EP1-
4, DP1, FP, IP and TP were calculated as ratios to the
corresponding β-actin mRNA level.
Western blot analysis of PG receptor protein expressions
The hippocampi (50 mg) were added with 0.5 mL of a
tissue lysate solution (Beyotime) and then the proteins
were extracted, followed by centrifugation at 14,000 × g
and 4°C for 10 min. The supernatant was collected for
Western blot analysis. The protein content was detected
using the BCA method according to the directions of
the protein detection kit (Beyotime).Then proteins were separated by sodium dodecyl sulfate
polyacrylamide gel electropheresis (SDS-PAGE) with 5%
stacking gel and 10% separating gel. The proteins were
transferred to polyvinylidene difluoride (PVDF) mem-
branes, which were blocked for 1.0 h with PBS containing
5% fat-free milk (weight/volume). The blots were incubated
at 4°C overnight with primary antibodies at dilution 1:300
for TP, IP, EP3 and DP1, at 1:400 for EP2, EP4 and
mPGES-1, at 1:500 for FP, and at 1:1000 for β-actin. The
blots were then incubated at 37°C for 2 h with a secondary
antibody at 1:2000 for β-actin, and 1:5000 for PG receptors.
The immunoreactive bands of PG receptors and β-actin
were visualized with a BeyoECL plus chemiluminescence
detection kit, and the optical density bands were detected
using a BioRad gel imaging and analysis system. The pro-
tein levels of PG receptors were calculated as ratios to the
corresponding β-actin protein level.
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All data are expressed as means ± standard deviation
(SD). Statistical analysis was carried out with SPSS 17.0
(IBM Corporation, Armonk, NY, USA). Between-group
differences in behavior test were evaluated by two-way
analysis of variance (ANOVA). Except for the behavior
test, between-group differences were evaluated by one-
way ANOVA and then Student’s t-test. P < 0.05 was con-
sidered significant.
Results
Spatial learning and memory functions of rats
At the stage of spatial learning function test from d 3 to d
4, the time for the Al-treated mice to learn to navigate the
maze was significantly prolonged (p < 0.05 and p < 0.01);
at the stage of spatial memory function test on d 5, the ex-
ploring time was significantly longer (p < 0.01) compared
with the control group (Table 2).
Morphological changes of rat hippocampus
In the control group, the hippocampal nerve cells were
closely arranged and well structured, and the morpho-
logical structure kept clear and intact. However, in the
Al-treated group, the nerve cells of hippocampal CA1
subfield were found with significant karyopyknosis and
loss (Figures 1a and b).
SOD activity and MDA content in rat hippocampus
As shown in Table 3, hippocampal SOD activity signifi-
cantly decreased and MDA content significantly in-
creased in the Al-treated group compared with the
control group, P < 0.05.
Levels of PGE2, PGD2, TXB2, 6-keto-PGF1α, and PGF2α in
rat hippocampi
The levels of 6-keto-PGF1α, PGE2, TXB2, PGF2α and
PGD2 in rat hippocampi in the Al-treated group signifi-
cantly increased by 251.20%, 179.76%, 81.17%, 80.93%
and 76.38%, respectively, compared with the control
group (Table 4).
Expression of PG synthase mRNAs in rat hippocampi
The rat hippocampal mRNA expressions of TXAS,
mPGES-1 and PGIS significantly increased by 53.45%,
48.78% and 27.27% respectively in the Al-treated group
compared with the control group (Figure 2).Table 2 Changes of spatial learning and memory function of
Exploring time(s)
Day 1 Day 2
Control group 71.88 ± 12.33 47.55 ± 17.54
Al-treated group 75.84 ± 10.42 52.63 ± 19.49
Data are expressed as mean ± SD of seventeen individual experiments. ∗P < 0.05 co
corresponding control group.mRNA and protein expressions of PG receptors in rat
hippocampi
The rat hippocampal mRNA expressions of EP2, EP4,
DP1 and IP significantly increased by 94.12%, 72.41%,
38.00% and 27.27%, respectively, while the mRNA expres-
sions of EP3, FP and TP significantly decreased by 36.99%,
15.38% and 15.22%, respectively in the Al-treated group
compared with the control group (Figure 3).
The rat hippocampal protein expressions of EP2, DP1
and IP increased significantly by 79.41%, 53.49% and
38.04%, respectively, while the protein expressions of
EP3 and FP significantly decreased by 40.90% and
39.66%, respectively in the Al-treated group (Figure 4).
Discussion
Any morphological alteration of hippocampal neurons will
result in cognitive impairment, which is the most common
hallmark for brain damages and neurodegeneration [37].
Therefore, in this study, we observed the changes of neu-
roinflammation, oxidative stress and neuronal loss in
chronic aluminium gluconate-overloaded rat hippocampi.
The experimental results show that chronic aluminium
gluconate administration not only caused significant hip-
pocampal neuron damage and oxidative stress response in
rats, but also resulted in the impairment of spatial learning
and memory functions. These results are similar with our
previous study [11].
Aluminum overload caused a significant reduction of
SOD activity and a significant increase of MDA content.
Our previous study shows that chronic aluminium glu-
conate exposure caused significant increase of Al, Fe,
Mn, Cu and Zn levels in rat hippocampi [11]. The brain
accumulation of Al, Fe, Mn, Cu and Zn could induce a
significant oxidative stress, which will cause tissue dam-
age and AA formation by degradation of cell membrane
phospholipids.
our results show that PGD2 level is the highest in nor-
mal rat hippocampus, followed by PGE2, PGF2α, TXB2
and 6-keto-PGF1α. Compared with the control group,
the treatment of aluminium gluconate significantly in-
creased rat hippocampal 6-keto-PGF1α, PGE2, TXB2,
PGF2α and PGD2 levels by 251.20%, 179.76%, 81.17%,
80.93% and 76.38%, respectively. Similarly, PGD2 was
also the most abundant prostanoid in rat brain tested by
gas-chromatography-mass spectrometry (GC-MS) [38].
PGD synthase (PGDS) has two isoenzymes of L-PGDSrats caused by aluminium gluconate overload (n = 17)
Day 3 Day 4 Day 5
22.33 ± 10.12 18.37 ± 8.39 15.03 ± 4.55
36.39 ± 19.65* 31.67 ± 16.84** 29.08 ± 17.56**
mpared with corresponding control group; ∗∗P < 0.01 compared with
Figure 1 Morphological changes of rat hippocampal neuron induced by aluminium gluconate overload. (a) Representative graph of
HE-stained CA1 section, 400×. Scale bars = 50 μm. Arrow indicates cell karyopyknosis. Dead nerve cells are characterized by eosinophilic changes; for
instance, nerve cells became deep and red with nuclear pyknosis and nucleoli disappearance under light microscopy. (b) Data showing the cell death
rate (n = 4). Data are expressed as mean ± SD of four individual experiments. ∗P < 0.05 compared with control group.
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and neurons [39], and the inhibition of its activation and
expression could abate neuronal injury [40,41]. However,
L-PGDS is not the major part responsible for PGD2 for-
mation and does not influence the effects of PGD2 [42].
H-PGDS is abundantly expressed in the microglia of
cerebellum and the hippocampal neurons of CNS [43].
PGD2 functions by activating two G-protein-coupled re-
ceptors viz. DP1 and DP2. DP1 and DP2 have opposite
effects on neurons subjected to injury factors. As re-
ported, physiological concentrations of PGD2 and a se-
lective DP1 agonist BW245C protect the hippocampalTable 3 Changes of SOD activity and MDA content in rat
hippocampus caused by aluminium gluconate overload
(n = 4)
SOD (U/mg prot) MDA(nmol/mg prot)
Control group 40.06 ± 4.31 2.70 ± 1.40
Al-treated group 26.02 ± 7.61* 4.64 ± 0.70*
Data are expressed as mean ± SD of four individual experiments. ∗P < 0.05
compared with control group.neurons from glutamate toxicity. Meanwhile, the activa-
tion of DP2 will cause significant neuron loss [43]. DP1
(−/−) mice are in a larger infarct size than wild-type
mice subjected to middle cerebral artery occlusion
(MCAO)-induced brain damage [44]. Young and aged
DP1-deficient mice are more susceptible to excitotoxi-
city than controls, and DP1 agonist will attenuate both
acute and chronic brain damages [45]. Our experimental
data show that PGD2 content and DP1 mRNA/protein
expressions in rat hippocampal neurons significantly in-
creased in the Al-treated group compared with the con-
trol group. However, the importance of the change of
PGD2/DP1 signaling pathway is unclear in rats with
brain damage caused by chronic aluminium gluconate
overload. Combined with previous studies, we think that
the elevation of PGD2 level resulted from the increase of
COX expression and PGH2 level. Moreover, aluminium
gluconate administration caused a protective increase of
DP1 expression. These results indicate that the PGD2/
DP1 signaling pathway is protective against brain dam-
age induced by chronic aluminium gluconate overload.
Figure 2 Expression of PG synthase mRNA in rat hippocampus (n = 4). The expression of PG synthase mRNA was measured by RT-PCR. The
middle band on the PCR images is a marker. The relative mRNA level of PG synthase was standardized to endogenous β-actin mRNA for each
sample. Data are expressed as mean ± SD of four individual experiments. Al administration induced a significant increase of TXAS, mPGES-1 and
PGIS compared with the control group (∗P < 0.05).
Table 4 Changes of PG levels in rat hippocampus caused by aluminium gluconate overload (n = 4, ng/g tissue)
PGD2 PGE2 PGF2α 6-keto-PGF1α TXB2
Control group 101.47 ± 38.01 42.09 ± 6.92 24.23 ± 9.20 7.91 ± 0.93 18.22 ± 5.86
Al-treated group 178.97 ± 26.44* 117.75 ± 24.51** 43.84 ± 12.74* 27.78 ± 4.90** 33.01 ± 4.62*
Data are expressed as mean ± SD of four individual experiments. ∗P < 0.05 compared with corresponding control group; ∗∗P < 0.01 compared with corresponding
control group.
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Figure 3 Expression of PG receptors mRNA in rat hippocampus (n = 4). The mRNA expression of PG receptors was measured by RT-PCR. The
middle band on the PCR images is a marker. The relative mRNA level of PG receptors was standardized to endogenous β-actin mRNA for each
sample. Data are expressed as mean ± SD of four individual experiments. Al administration induced a significant increase of EP2, EP4, DP1 and IP
levels and a significant decrease of EP3, FP and TP levels compared with the control group (∗P < 0.05).
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number of experiments.
PGE synthases (PGES) consist of three major iso-
zymes: microsomal PGES-1 (mPGES-1), mPGES-2 and
cytosolic PGES (cPGES). mPGES-1 is inducible, while
mPGES-2 and cPGES are constitutive. PGE2 as the
product of PGES exerts complex effects through four
PGE receptors: EP1, EP2, EP3, and EP4. Our results show
that PGE2 content in rat hippocampus significantlyincreased in the Al-treated group vs. the control group.
Administration of aluminium gluconate resulted in
significant increase of mPGES-1, EP2 and EP4 mRNA
expressions and EP2 protein expression, and also
caused significant decrease of EP3 mRNA and protein
expressions. It was similarly reported that protein and
mRNA expressions of COX-2 and mPGES-1 signifi-
cantly increased in postmortem brains of AD patients
[10]. Activation of EP1 which is expressed widely in
Figure 4 Protein expression of PG receptors in rat hippocampus (n = 4). The protein expression of PG receptors was measured by Western
blot. The relative protein level of PG receptors was standardized to endogenous β-actin protein for each sample. Data are expressed as mean ± SD of
four individual experiments. Al administration induced a significant increase of EP2, DP1 and IP levels and a significant decrease of EP3 and FP levels
compared with the control group (∗P < 0.05).
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murine primary cortical neurons and a human neuro-
blastoma cell line [46]. Conversely, EP1 is the neurotoxic
effector of downstream COX-2, and the blockage of EP1
signaling protects against cerebral ischemic damage and
Aβ neurotoxicity [16,17]. EP2 signaling is very important
for synaptic plasticity, and its selective allosteric potentia-
tor has a neuroprotective effect [47,48]. However, activa-
tion of PGE2 could stimulate the production of Aβ by
coordination with EP4 [21]. The cerebral infarct volume
decreases in EP3 (−/−) mice [49]. Selective activation of
EP3 can dose-dependently increase the infarct volume inMCAO mice [50]. However, another study shows that
the infarct volume in EP3 (−/−) mice does not obviously
change [51]. Oral administration of a specific EP4 antag-
onist caused an improvement of learning and memory
functions and a decrease of brain Aβ level in APP23
mice [23]. Obviously, knockout of EP4 and administra-
tion of an EP4 antagonist can both suppress the develop-
ment of encephalomyelitis [22]. However, it is still
unclear whether the decrease of EP3 expression and the
increase of EP2 and EP4 expressions are beneficial or
harmful to treatment of chronic brain damage. There-
fore, more experiments with agonists and antagonists of
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therapeutic values from the changes of EPs.
PGF2α is a major PG biosynthesized by PGFS from
PGH2. An immunohistological study shows that PGF2α
production in hippocampal neurons can be immediately
induced by injection of kainic acid, and that PGF2α-
immunopositive neurons also express COX-2 and FP
[52]. Studies on FP blockade and FP knockout in vivo
and in vitro suggest that FP contributes to the preven-
tion of ischemic and excitotoxic brain damages [31,32].
In our study, however, chronic aluminium gluconate ad-
ministration caused a significant increase of PGF2α level
and obviously downregulated the mRNA and protein ex-
pressions of FP in rat hippocampus. It is still unclear
whether the activation of FP signaling pathway is benefi-
cial or harmful for acute and chronic brain damages.
PGI2 or prostacyclin, which is derived from AA via
PGIS, exerts its important physiological functions by act-
ing mainly on IP. Besides endothelial cells, PGIS is also
abundantly expressed in hippocampus and cortex neu-
rons companied with the expression of IP. Cerebral is-
chemia reperfusion insult will cause a delayed and
transient induction of PGIS in hippocampus and cortex
neurons [30]. COX-1/PGIS adenoviral gene transfer to
substantia nigra will prevent dopamine depletion and be-
havioral deficits induced by 6-OHDA in rats [53]. The
infarct volume and behavioral damage in IP−/−mice
were significantly enhanced compared with the wild-
type mice, and administration of beraprost, a selective IP
agonist, significantly improved the neurological deficit
and decreased the infarct volume in wild-type mice [54].
Our experiments also show that 6-keto-PGF1α content
and the expressions of IP mRNA and protein obviously
increased in the hippocampi of the Al-treated rats.
These results suggest that activation of PGIS/IP signal-
ing pathway will prevent brain damage.
Evidence shows that postsynaptic TP activation will in-
hibit synaptic transmission while presynaptic activation
will promote the glutamate release, which mediates the
excitotoxic damage to the brain [29]. Administration of
a selective TP antagonist could prevent ischemic stroke
[54]. The present study shows that the TXAS mRNA ex-
pression and TXB2 content in the Al-treated rat hippo-
campi increased significantly. The hippocampal mRNA
levels of TP in the Al-treated rats significantly decreased
but the protein levels were unchanged. These results
suggest that the intervention of the TXAS/TP signaling
pathway has no important value for treatment of chronic
brain damage induced by aluminium gluconate overload.
In conclusion, our study confirms the disturbance of a
PGS/PGs/PG receptors signaling pathway in rat hippo-
campi caused by chronic aluminium gluconate overload
and this may be involved in the mechanism of alumin-
ium neurotoxicity. However, the value of such changesfor this signaling pathway is not completely clear. We
are starting a series of studies with agonists and antago-
nists of DP1-2, IP, FP, TP and EP1-4, and aim to explore
the therapeutic value of these changes of PGS/PGs/PGs
receptors signaling pathways for treatment of acute and
chronic brain damages in rats.
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